Skip to main content

Utdanning

  • Cand.med ved Universitet i Bergen
  • Spesialist i revmatologi
  • Doktorgrad (PhD) ved Institutt for klinisk medisin, Universitetet i Oslo

Stilling

  • Overlege ved Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet sykehus
  • Post doc, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet Sykehus

Interessefelt

  • Revmatologi
  • Utfallsmål
  • Prediksjon
  • Oppfølging og behandling
  • Randomiserte kontrollerte studier

E-post

Telefon

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP1 - Behandlingsstudier

ARCTIC

Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging

Prosjektleder:
Espen A. Haavardsholm
WP1 - Behandlingsstudier

ARCTIC REWIND

10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.

Prosjektleder:
Espen A. Haavardsholm
WP5 - Strategier for digital oppfølging

NOR-Flare

Avstandsoppfølging av pasienter med revmatoid artritt

Prosjektleder:
Anne Therese Tveter

Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad


The Lancet Rheumatology

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Lena Bugge Nordberg, Till Uhlig, Tore Kristian Aaserud Kvien


RMD Open

2024

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg


Annals of the Rheumatic Diseases

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Daniel H. Solomon, Désirée Van Der Heijde


Journal of the American Medical Association (JAMA)

2023

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Shrikant Kolan, Gaoyang Li, Franco Grimolizzi, Joseph Sexton, Tore Kristian Kvien, Guro Løvik Goll


Frontiers in Pharmacology

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

Nina Beate Paulshus Sundlisæter, Ulf Gunnar Sundin, Anna-Birgitte Aga, Joseph Sexton, Hilde Berner Hammer, Till Uhlig


RMD Open

2022

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

Karen Holten, Nina Beate Paulshus Sundlisæter, Siri Lillegraven, Joseph Sexton, Lena Kristine Bugge Nordberg, Ellen Moholt


Annals of the Rheumatic Diseases

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad


Journal of the American Medical Association (JAMA)

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy

Ulf Gunnar Sundin, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Lena Kristine Bugge Nordberg, Hilde Berner Hammer


RMD Open

2021

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

Nina Beate Paulshus Sundlisæter, Inge Christoffer Olsen, Anna-Birgitte Aga, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde


Rheumatology

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde


Annals of the Rheumatic Diseases

2018

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

Maria Karolina Jonsson, Nina Beate Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Inge Christoffer Olsen


Annals of the Rheumatic Diseases

2017